Advicenne (Euronext Growth Paris:ALDVI), a specialty pharmaceutical company focused on rare renal diseases, announced on Tuesday that it has secured key regulatory milestones for its ADV7103 drug in the United States.
The US Food and Drug Administration (FDA) has said that European clinical data can be used to support an application for registration in dTRA (Distal Renal Tubular Acidosis) without further clinical trials.
Additionally, the positive orphan drug designation in cystinuria has paved the way for productive discussions with the FDA on development in this indication.
These advancements are poised to bolster Advicenne's partnership prospects for commercialising ADV7103 in the US. The company has already garnered interest from potential partners in the region.
Johnson & Johnson submits DARZALEX FASPRO supplemental Biologics License Application to FDA
Modalis Therapeutics receives FDA Rare Pediatric Disease designation for MDL-101 in LAMA2-CMD
Adicet Bio announces enrollment for Phase 1 trial to evaluate ADI-001 in autoimmune diseases
Astria Therapeutics secures FDA Orphan Drug Designation for Nnavenibart in HAE treatment
Bristol-Myers Squibb's schizophrenia drug Cobenfy receives US FDA approval
Pharming receives UK marketing authorisation for Joenja
DURECT Corporation announces design of upcoming registrational Phase 3 larsucosterol trial
EydisBio's EYD-001 receives US FDA Orphan Drug Designation
Biocon BIologics unveils new dermatology data at EADV Congress 2024
Implantica advances RefluxStop with CE mark study results and prepares for FDA submission
NeuroSense Therapeutics receives US patent for novel PrimeC formulation
IntraBio's Aqneursa receives US FDA approval
Priovant Therapeutics enrols first patients in brepocitinib CLARITY study
Elevation Oncology's EO-3021 receives US FDA Fast Track designation
Lantern Pharma secures FDA designations for rare paediatric cancers